Truth Detector
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Wow-after all of the recent days of no trading volume, someone actually stuck their neck out and bought 3000 shares and invested a whopping $24 to do so-impressive to say the least!!
Load up the truck, folks-this one is about to take off! lol
For me and until proven otherwise via some kind of encouraging news, the stock is nothing more than a trading vehicle for those who are able to buy near the bid and sell near the ask assuming that is possible.
On lots of days the volume has been zero or a token number of shares traded.
This tells me that there is rightfully not much interest in this company or purchasing its stock for very obvious reasons.
Personally I don't get excited very much either way if the stock is at .005 or for that matter a little over $.01.
Imo without any positive news of any kind, the relatively slight price fluctuations don't mean a good god damn no matter what type of analysis/hope one is using/feeling on a stock like this.
If the stock gets above $.02 with some trading volume well into the millions of shares, and closes there for a couple of days, it might mean something.
Thanks for the helpful link!
I still like this l2...
What do you mean by this?
Thanks
One of the reasons I am hanging in there is because imo even if they don't get the financing, I got to believe that the patents and intellectual properties of what they have alone are worth a lot more than current stick price.
60 shares traded so far.
As I suspected virtually no one really gives a rat's ass about inconsequential short term news like this at this point.
Actually I am surprised that the stock price isn't down, but then again how much lower can it go at this point as long as the company is still in business.
The good news is that you got your wish.
I am not a financial wizard by any means, but I cringe when I see 100 million restricted shares as part of any deal for obvious reasons.
Whether this dal is a Hail Mary or not is anyone's guess.
Imo at this point the vast majority of folks including myself aren't going to buy or at least with any volume/conviction until/if/when company releases some news to give them conviction/incentive to buy.
Imo we haven't heard anything positive about this company in the way of good news in at least a year.
Although I am trying to stay positive, we have these short term blips in the stock prices before at higher prices with nothing to show for it subsequently.
Perhaps this time will be different, but for now personally, I am simply holding onto the shares I have, which are far from chump change in total.
Imo relative to the price of the stock the total volume including today is still paltry.
I would like to see some hundred thousand or more blocks of shares trade to possibly indicate that this little upward movement over the last week means something.
If they get the financing needed, imo sky is the limit.
Without it, well kiss our investment 99.9% gone.
I hope you folks who are optimistic are right, but until/if I see some news that this company is making some progress, I consider these occasional blips as nothing more than market manipulation ands attempts of mm's to convince folks that positive news will be released soon.
The illegal shorting which goes on with this company doesn't help either.
All I know is that I am simply sitting on my hefty six digit number of shares accumulated over the years.
Even with the little rally of late, I have not yet raised my hopes or expectations.
If and when I see some sustained upward price movement on some substantial buy orders and big daily volume-I don't mean several hundred or even a million shares traded in a day at current price level.
That said, good luck to all of us-you never know.
Corrected line from previous post:
I am neither adding nor selling any of my shares at this point and do not intend to without any news one way or the other from the company.
I haven't checked in for a while because well the stock price hasn't "exactly" done that well and no encouraging news to speak of.
I am a retail investor with a pretty hefty six figure number of shares and am obviously pretty far behind like everyone else(what an understatement that is lol).
I am neither adding nor selling any of my shares at this point and do not intend to without any news one way or the other from the country.
I did email the CEO a few months ago to see what he would offer.
He obviously couldn't tell me anything which isn't known to everyone else, but he did say that there was a lot of illegal shorting going on which they were looking into-that was it.
Anyways, to conclude, I would be lying to say that I am optimistic at this point based on stock price, and will be pleasantly surprised if somehow this company does ever get its products to market and is profitable.
Good luck to all!!
ps FWIW I also think on some days mm games/manipulation are going on with this stock price in order to get some lunch money and to pay the bills so to speak.
I have quite a bit of this stock for a retail investor and am totally dissatisfied with the lack of progress reports from the company as well as the rampant manipulation of the stock price which at times results in bid and ask which are more than .05 apart-quite a bit for a stock trading at these levels!!
Yeah Neos has done well and I expect it to go much higher unlike ELTP which I bought at around $.85 when I actually trusted laser's honesty when he said it was about to take off..
Just curious-what is the update for this company and stock price and ticker symbol?
Thanks for the update.
Some of us do want to be updated of the status of our now merged company from time to time for possible investment purposes assuming of course that we are still alive if and when the investment opportunity arises. lol
Unless this is all made up with no merit to it, for me this is good news:
PetLife Announces its All-natural 'Cancer Cocktail' With Applicability to Pet and Human Markets
The Company may be the first to offer an all-natural 'cancer cocktail' combining the therapeutic benefits of the plant and animal kingdoms
Jun 14, 2017, 6:00am EDT
HANCOCK, Maryland, June 14, 2017 /PRNewswire/ --
PetLife Pharmaceuticals, Inc. (OTCQB: PTLF) (the "Company"), a developer of a new generation of high potency veterinary cancer medications and nutraceuticals for pets, reports on its solution to the ever increasing problem of drug resistance and high toxicity in the treatment of cancer in pets and humans. Each year, in the U.S. alone, more than eleven million cases of cancer in dogs and cats are reported, a number that continues to increase annually.
PetLife's new patent-pending formulation has created a 'cancer cocktail' combining both Blue Scorpion Venom Chlorotoxin with plant-based phytonutrients. Preliminary testing has shown inhibition against certain cancer cell line studies without toxicity. Across the world, researchers have recognized that many cells which cause disease, have the ability to become resistant to treatment when only one drug is used. Combination therapy is increasing, recommended for the treatment of both neoplastic (cancer) and infectious disease. The 'HIV Cocktail', which changed the world's approach to the treatment of HIV, is a similar approach comparison. PetLife's new 'cancer cocktail' may prove to be the non-toxic alternative to the harmful and sometimes deadly side effects of radiation and chemotherapy. The patent pending formulation of PetLife's new 'cancer cocktail' has the curious ability to bind selectively to cancer cells and inhibit their growth demonstrating little to no side effects to the patient.
For hundreds, if not thousands of years, plant-based medicinals have formed the foundation of therapeutic treatment in the Chinese, Native American and Ayurvedic traditions. More recently, scientists have discovered the mode of action of many of these therapies. In many cases, the chemical compounds have been manipulated or synthesized to create new chemical entitles ("NCE"). Along with the creation of NCEs comes the inherent risk of unintended consequences and adverse reactions. By maintaining an all-natural formulation, PetLife intends to capture the therapeutic benefit of plant-based therapy without the creation of any unintended consequences. Our team has identified certain phytonutrients which can work synergistically with Blue Scorpion Venom for inhibition of cancer cell growth.
"Our new formulation, RX002CxN, will become the basis of PetLife Pharmaceutical's new product portfolio, Vitalzul[TM], a novel treatment option for the treatment of cancer and potentially other indications. The low toxicity of our formulation gives additional benefit. Given the comparative biology of animals and humans, it is our hope that success in treatment of cancer in animals will lead to similar results in humans. Our new formulation has been designed with both human and animal applications in mind. Once testing is completed, the Company will strategically determine the best course of development in both the pet and human markets," stated Dr. Vivekananda Ramana, Chief Medical Officer of the Company.
"This groundbreaking, patent pending biotechnology will serve as the core ingredient in our pharma product Vitalzul[TM] once we complete the much anticipated FDA trials. It is well known that animal research and studies are the foundation of human applications. Our first goal is to complete the successful testing, FDA application and commercialization for the benefit of animals. Then, we will move aggressively in expanding our research in the human arena, where we anticipate strong interest from industry leaders," added Dr. Salvagno.
About PetLife Pharmaceutical
PetLife Pharmaceuticals, Inc. (PTLF) (http://www.PetLifePharma.com) is a registered U.S. Veterinary Pharmaceutical company. PetLife's mission is to bring its new, non-toxic, bioactive nutraceuticals and prescription medications to the world of veterinary oncology with the ultimate goal of preventing cancer and extending the life of pets suffering from cancer while improving their quality of life. The Company's first product, Vitalzul[TM], is currently in testing. Vitalzul[TM]'s active ingredients have been shown to have activity against several different cancer cell lines. In the U.S. alone, consumer spending on domestic companion animals reached over $60 billion in 2015 with over $29 billion spent on veterinary care and medications. PetLife's acquired brand, Dr. Geoff's Real Food for Pets will launch in 2017. PetLife Scorpion Ranchâ„¢ will break ground in 2017. PetLife anticipates incorporating Vitalzul[TM] in a new and advanced therapeutic pet food line in 2019.
Forward looking statement:
This press release contains certain "forward-looking statements," as defined in the United States PSLRA of 1995, that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. The economic, competitive, governmental, technological and other factors identified in the Company's previous filings with the Securities and Exchange Commission may cause actual results or events to differ materially from those described in the forward-looking statements in this press release. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Company Contact
Clifford Price
clifford@petlifepharma.com
+1-844-473-8543 ext. 701
SOURCE Petlife Pharmaceuticals, Inc.
Petlife Pharmaceuticals Inc : PetLife Completes Its TV Commercial for Newly Acquired Dr. Geoff's by PetLife, Preparing for Regional Launch
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Clip of TV Commercial at http://www.petlifepharma.com/drg
HANCOCK, MD / ACCESSWIRE / June 6, 2017 / PetLife Pharmaceuticals, Inc. (OTCQB: PTLF) (the "Company"), a developer of a new generation of high-potency veterinary cancer medications and nutraceuticals for pets, announced today that its wholly owned subsidiary, Dr. Geoff's by PetLife, Inc. ("Dr. Geoff's by PetLife"), PetLife's product line of natural pet food, supplements, and treats, has initiated its comprehensive product rollout.
The Company, through its wholly owned subsidiary, will proceed with an initial regional pilot launch, followed by a national rollout. The introductory product launch will focus on two Superfood Supplements: ImmunoPower? and Antioxidant Boost?, and several canned food products, with extensive plans for product line expansion.
ImmunoPower? is a unique, proprietary blend of micro-ingredients that equips the pet's body with the nutrients to support overall well-being and is formulated to deliver as much antioxidant power as possible.
Antioxidant Boost? uses the power of antioxidant vitamins, antioxidant chelated minerals, phytonutrients, digestive enzymes and probiotics combined in this unique super-food.
The TV commercial for the product launch has been prepared and completed by a world-class production and media team. Media buys are currently being sourced to provide the best value. For a short segment view of the TV commercial, visit: http://www.petlifepharma.com/drg/. This TV commercial will be incorporated into an infomercial and promoted through social media.
"The strategic advantage of launching our food product in advance of the anticipated FDA approved Vitalzul? is that it provides the Company the advantage of revenues, profits and enhanced cash flow," stated Dr. Ralph Salvagno, CEO of PetLife. "Brand awareness is a key component for success given the competitive market in the pet food industry. We believe that our core product, Vitalzul?, when infused into pet food, will create an extraordinary, proprietary and world class product for pets and their owners. The Company plans to offer two additional food products infused with Vitalzul?: a veterinary prescribed, therapeutic form for pets with cancer, and a product proposed as a preventive for older dogs. Statistically, 49% of dogs and 38% of cats will be stricken with some form of cancer after the age of 10."
PetLife plans to roll out a complete line of 25 foods, treats, supplements, and pet accessories. These include nutraceuticals, shampoos, creams, sprays, and other natural products for dogs and cats. PetLife is in discussions with third parties to provide specific complementary products that would not be "just another product on the shelf" but those that have proprietary properties that will enhance PetLife's reputation as a quality provider of natural-based solutions for animal diseases and conditions.
About PetLife Pharmaceuticals, Inc.
PetLife Pharmaceuticals, Inc. (PTLF) (www.PetLifePharma.com) is a registered U.S. Veterinary Pharmaceutical company. PetLife's mission is to bring its new, non-toxic, bioactive nutraceuticals and prescription medications to the world of veterinary oncology with the ultimate goal of preventing cancer and extending the life of pets suffering from cancer while improving their quality of life. The Company's first product, Vitalzul?, is currently in testing. Vitalzul?'s active ingredients have been shown to have activity against several different cancer cell lines. In the U.S. alone, consumer spending on domestic companion animals reached over $60 billion in 2015, with over $29 billion spent on veterinary care and medications. PetLife's acquired brand, Dr. Geoff's Real Food for Pets, is launching in 2017. PetLife Scorpion Ranch? is breaking ground in 2017. PetLife anticipates incorporating Vitalzul? in a new and advanced therapeutic pet food line in 2019.
Forward looking statement:
This press release contains certain "forward-looking statements," as defined in the United States PSLRA of 1995, that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. The economic, competitive, governmental, technological and other factors identified in the Company's previous filings with the Securities and Exchange Commission may cause actual results or events to differ materially from those described in the forward-looking statements in this press release. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Company Contact
Clifford Price
clifford@petlifepharma.com
844-473-8543 ext. 701
SOURCE: PetLife Pharmaceuticals, Inc.
©
It appears that the despicable mm aholes who control the price movement of this stock for their own benefit are up to their old tricks again and/or are trying to scare people away.
Trust me folks-I have been investing since the 70's and have seen these tactics way too many times to count.While I did sell some of my shares in the fifties, I bought most of them back today in th 30's and will add more if stock drops some more.
If you like what this company is doing and ae impressed by the writeups, then well draw you own conclusions as what to do.
Interesting and informative statement from company:
HANCOCK, MD / ACCESSWIRE / May 28, 2017 / PetLife Pharmaceuticals, Inc. (OTCQB: PTLF) (the "Company," "We"), a developer of a new generation of high potency veterinary cancer medications and nutraceuticals for pets, announced the Company's comments on recent developments in its stock price and trading performance.
The Company is confident that the main reason of the investors' interest in its stock is our business performance, which is reflected on the Company's website and its press releases (http://www.petlifepharma.com/investor-relations/), as well as has been presented to numerous investors during road shows conducted by the Company in several cities. We have been pleased to announce a string of positive developments with our business, which we believe to have been the procuring cause of investors? buying our stock at or about the times when the Company announced such good business-related news or has investor presentations. At the same time, we became aware of the efforts to promote our stock by various penny stock-touting websites, newsletter publishers and IR marketing services, unknown to and unaffiliated with the Company. We first noticed that activity in February 2017, and observed the same type of efforts recently.
It is our understanding that such promotional activities happen when companies quoted on OTC Markets publish news, which cause the prices of their respective stocks to move. Third party stock promoters scan the market, mention stocks, which they find on the move, to their subscribers, claim credit for such moves, and solicit payments from both subscribers and others.
We do not believe that such promotional activities unauthorized, unrelated to, and not approved by the Company, can cause a significant number of investors to buy our stock. We strongly believe that the main reasons for the investors buying the stock of our Company have been our business performance reflected in press releases and presented to multiple accredited investors during our road shows. Unfortunately, the activities of third party stock promoters seeking to exploit positive developments in our business and appreciation of our stock price have a clear adverse effect on our stock price as follows. Apparently, market makers engaged in predatory short selling are among the most active subscribers to the services of such stock promoters. For example, our stock price moved up recently as the result of the positive press release published on May 23, 2017. That was picked up and exploited by some stock-touting websites and already on May 25, 2017 (according to FINRA's web page tracking the short-selling at http://regsho.finra.org/FORFshvol20170525.txt), 226,257 shares of our stock were sold short in one day. That is 60% of the daily volume of trading on that date. We have also observed what appears to be a very active short-selling activity on May 26, 2017, when another positive press release caused our stock price to move up. The Company may be addressing this with the market regulators, including naming the most active short-selling market makers, in a hope that both OTC Marketplace and FINRA interfere with their predatory market price manipulations.
It is our obligation to OTC Marketplace and the investors to hereby state that after inquiry of the Management of the Company, we have determined that the directors, control persons, its officers, directors, or any controlling shareholders (defined as shareholders owning 10% or more of the Company?s securities) have not, directly, or indirectly, been involved in any way (including payment of a third-party), with the creation or distribution of promotional materials related to the Company and its securities. Furthermore, after inquiry of management, we have determined that the directors and control persons, the Company, its officers, directors or any controlling shareholders have sold or purchased the Company's securities within the past 90 days.
In order to further address the concerns related to the unauthorized promotional activities the Company will be putting out a SEC Form 8-K enumerating all the relevant press releases as well as naming the list of third party providers engaged by the Company to provide investor relations services, public relations services, marketing, or other related services, including the promotion of the Company or its securities, since January 1, 2016. We are also planning to address in the same SEC Form 8-K filing, the detailed information about shares or convertible instruments issued by the Company allowing conversion to equity securities at prices constituting a discount to the current market rate at the time of the issuance.
Furthermore, the Company needs to draw attention of some materially inaccurate and outdated information, which has been included in the unauthorized and unapproved disseminations. In particular, the mentioning of ?Gain? of 349% relating to a historical stock price is materially incorrect as it fails to account for a 5:1 reverse merger that occurred during the interval in question. Additionally, as part of our negotiations with our former CEO, we have removed all mentions of Escozine from the approved Company literature, including any claims made by the manufacturer of Escozine. The Company abandoned the use of the term "organic" in its authorized publications. The use of the term "Escozine for Pets" was abandoned by the Company in favor of VitalzulTM. The Company does not currently describe its products as ?a preventative and treatment for cancer." Additionally, the Company has no opinion on the accuracy of any technical analysis represented in some unauthorized disseminations. No technical analysis has been performed by the Company regarding its stock.
About PetLife Pharmaceuticals, Inc.
PetLife Pharmaceuticals, Inc. (PTLF) (www.PetLifePharma.com) is a registered U.S. Veterinary Pharmaceutical company. PetLife's mission is to bring its new, non-toxic, bioactive nutraceuticals and prescription medications to the world of veterinary oncology with the ultimate goal of preventing cancer and extending the life of pets suffering from cancer while improving their quality of life. The Company's first product, VitalZul?, is currently in testing. VitalZul's? active ingredients have been shown to have activity against several different cancer cell lines. In the U.S. alone, consumer spending on domestic companion animals reached over $60 billion in 2015 with over $29 billion spent on veterinary care and medications. PetLife?s acquired brand, Dr. Geoff's Real Food for Pets, will incorporate VitalZul? in its pet food line in 2018.
Forward looking statement:
This press release contains certain "forward-looking statements," as defined in the United States PSLR Act of 1995, that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. The economic, competitive, governmental, technological and other factors identified in the Company's previous filings with the Securities and Exchange Commission may cause actual results or events to differ materially from those described in the forward-looking statements in this press release. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Press Contact:
Clifford Price
Clifford@PetLifePharma.com
844-473-8543 ext. 701
SOURCE: PetLife Pharmaceuticals, Inc.
© Accesswire 2017
Good for you and my wishes for continued success.
I missed most of the first move up, but determined I would make up for it in the future.
Io was also behind going into today because I also bought some in the 30's.
Now howver I am siting on a nifty profit.
I sold a LITTLE bit just now at .43 because as they say it doesn't pay to get too greedy.
I am going to sit on the rest for now as I think the best is yet to come.
Wow-what a day so far!
Judos to all folks backed up the truck as I did in the teens and low twenties as I did and bought as many shares as you could and/or who those simply held on to what they had.
I agree again.
I am not a "big boy" by any means, but on my scale I did add nicely after calling the company and speaking to the CEO(I mentioned this in a recent previous post and liked what I heard)when the stock dipped into the teens.
I have learned over the many years I have been in the market that one has to be very careful in investing in speculative penny stocks because many of them are based on hype and bs only.
In this case though and being a pet lover(especially cats), I liked what I have read and the encouraging oncoming progress being made in this very important area in this multi billion dollars business.
Good luck to you and everyone invested in this-I feel vry confident here in this investment and have the patience and resources to do so.
If one is an instant gratification type investor, my advice is to invest in somethine else.
ps There is always the possibility that it could explode soon but that is not my modus operandi in investing.
I agree and have been adding nicely right along since the precipitous drop began.
Lets hope that today's rise is not simply market manipulation and is some yet to be announced good news.
The bad news is that the downdraft while continuing at a slower pace, is still tending downward.
Imo though any good news such as the type which propelled it in the first place a few months agom could result in at least a very quick double from current price level becauseof how thinly traded is it and the rampant manipulation we saw when it went to $.75 or more recently.
jmho
FWIW I just spoke to the CEO re: the company and the the huge dewcline in the stock price.
Obviously he couldn't comment too much on the stock price, but in speaking to him I did get a sense of optimism and that there would be some signficant positive news in the future.
While I am a fairly significant investor in this stock and like anyone else would like to see a return on my investment, please do not view what I just say as any kind of a pump and/or that I know anything that you people do not.
Do your own dd and invest according to your own criterion and risk tolerance.
Like any speculative stock(imo that is what it still is), this stock should be bought with discretionary money only, and one should never invest more than he or she can afford to lose comfortably if things do not work out.
Judging by fact that stock price is now day, in retrospect it looks like the whole rise was a mm hoax to try to get people to believe something was really up when in fact it was business as usual-not uncommon for a stock of this nature.
You are correct.
I may just take that $1.32 price as some kind of a psychic message that in time this is what I will get for my shares if I am patient. lol
I am not holding my breath on getting that price,thats for sure.
We are on in the same boat. lol
I was stunned to see that also in my TD Ameritrade and to see my overall account value jump off the table.
I don't see any news, and although I hope I am wrong, my gut feeling is that it is a misprint and/or some kind of reverse stock split about which I was unaware which caused the huge spike.
The current bid and ask is .25/.255, which also leads me to believe the $1.32 in a misprint.
I have a nine position in neos and already have a very nice profit.
Check it out.
I sold half my holdings the other day at a little over .50.
I just purhased them back.
I learned a long time ago to filter out the news and in this case short term fear and to buy and look ahead in a very promising company in a very promising industry.
The only sure thing is that somewhere along the way if the price continues to fall, at the very least there will be another takeover rumor which will give a quick spike to the stock price.
Its nice to hear from you folks and that all is well.
Things are fine for me also both in personal life and other investments even though I still miss this forum to some extent and its list of distinct characters.
Continued good luck to all in your investments, health, personal life and overall happiness!!
I along with some others told you folks it was over six months ago.
Sorry you lost,and hopefully learn a lesson and not live in a fantasy world of delusion when the writing is on the wall.
ps I lost also but at least was able to recover some of my money when things headed south.